400 related articles for article (PubMed ID: 33896023)
1. Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection.
Toyoda H; Yasuda S; Shiota S; Sone Y; Maeda A; Kaneoka Y; Kumada T; Tanaka J
Aliment Pharmacol Ther; 2021 Jun; 53(12):1309-1316. PubMed ID: 33896023
[TBL] [Abstract][Full Text] [Related]
2. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
[TBL] [Abstract][Full Text] [Related]
3. Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection.
Toyoda H; Yasuda S; Shiota S; Sone Y; Maeda A; Kaneoka Y; Kumada T; Tanaka J
Eur Radiol; 2022 Jul; 32(7):5016-5023. PubMed ID: 35142900
[TBL] [Abstract][Full Text] [Related]
4. Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments.
Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Kaneoka Y; Maeda A; Akita T; Tanaka J
Aliment Pharmacol Ther; 2018 Sep; 48(6):664-670. PubMed ID: 30047149
[TBL] [Abstract][Full Text] [Related]
5. Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study.
Kumada T; Toyoda H; Yasuda S; Tada T; Ogawa S; Takeshima K; Tanaka J; Chayama K; Johnson PJ
Aliment Pharmacol Ther; 2020 Jul; 52(2):359-370. PubMed ID: 32519782
[TBL] [Abstract][Full Text] [Related]
6. The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C.
Toyoda H; Tada T; Yasuda S; Mizuno K; Sone Y; Kaneoka Y; Maeda A; Akita T; Tanaka J; Kumada T
Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1232-1238. PubMed ID: 31588590
[TBL] [Abstract][Full Text] [Related]
7. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.
Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY
World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884
[TBL] [Abstract][Full Text] [Related]
8. Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver.
Shimizu Y; Arai K; Yamashita T; Yamashita T; Shimakami T; Kawaguchi K; Kitamura K; Sakai Y; Mizukoshi E; Honda M; Kitao A; Kozaka K; Kobayashi S; Kaneko S
Liver Cancer; 2020 Jun; 9(3):261-274. PubMed ID: 32647630
[TBL] [Abstract][Full Text] [Related]
9. Long-term persistence of hepatocarcinogenic potential of a non-hypervascular hypointense nodule on EOB-MRI after the eradication of hepatitis C virus.
Toyoda H; Yasuda S; Shiota S; Kumada T
Hepatol Res; 2022 Jan; 52(1):128-132. PubMed ID: 34472681
[TBL] [Abstract][Full Text] [Related]
10. Non-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma.
Iwamoto T; Imai Y; Igura T; Kogita S; Sawai Y; Fukuda K; Yamaguchi Y; Matsumoto Y; Nakahara M; Morimoto O; Ohashi H; Fujita N; Kudo M; Takehara T
Dig Dis; 2017; 35(6):574-582. PubMed ID: 29040990
[TBL] [Abstract][Full Text] [Related]
11. Presence of non-hypervascular hypointense nodules on Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma.
Inoue M; Ogasawara S; Chiba T; Ooka Y; Wakamatsu T; Kobayashi K; Suzuki E; Tawada A; Yokosuka O
J Gastroenterol Hepatol; 2017 Apr; 32(4):908-915. PubMed ID: 27787908
[TBL] [Abstract][Full Text] [Related]
12. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC.
Toyoda H; Kumada T; Tada T; Sone Y; Maeda A; Kaneoka Y
Hepatol Int; 2015 Jan; 9(1):84-92. PubMed ID: 25788383
[TBL] [Abstract][Full Text] [Related]
13. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of Gd-EOB-DTPA-enhanced MRI for evaluating the potential for early development of hepatocellular carcinoma after HCV eradication by direct-acting antiviral treatment.
Morimoto N; Miura K; Watanabe S; Tsukui M; Takaoka Y; Nomoto H; Murayama K; Hirosawa T; Goka R; Kunitomo N; Nakamura H; Sugimoto H; Isoda N; Yamamoto H
J Rural Med; 2019 May; 14(1):78-86. PubMed ID: 31191770
[No Abstract] [Full Text] [Related]
15. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
16. Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy.
Toyoda H; Kumada T; Tada T; Niinomi T; Ito T; Sone Y; Kaneoka Y; Maeda A
J Hepatol; 2013 Jun; 58(6):1174-80. PubMed ID: 23376360
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
18. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
Roche B; Coilly A; Duclos-Vallee JC; Samuel D
Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
[TBL] [Abstract][Full Text] [Related]
19. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
20. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
